J&J/Merck Developing Mevacor 20 Mg As OTC In U.S.
This article was originally published in The Pink Sheet Daily
Executive Summary
Merck exces say they will go after approval for higher dose than before because of a "much clearer benefit." FDA resubmission to be under review within a year.
You may also be interested in...
Round Two: Mevacor Switch Will Need To Quiet Questions On Non-Optimal Treatment
Undertreatment concerns remain biggest hurdle for Mevacor (lovastatin) switch sponsor J&J/Merck when the statin goes before a second advisory committee review expected in the next 12 months.
NDAC Approach To OTC Switches Highlighted At Corticosteroid Meeting
Panel review provides examples of different attitudes toward switches between OTC experts, other category-specific prescribers.